See the DrugPatentWatch profile for Efinaconazole
Efinaconazole, marketed as Jublia, received its approval date from the U.S. Food and Drug Administration (FDA) on June 10, 2014 [1]. This antifungal medication is prescribed for the topical treatment of onychomycosis, a fungal infection of the toenails [1].
When does Efinaconazole (Jublia) patent expire?
The primary patent protecting Efinaconazole expired on January 23, 2023 [2]. However, other patents related to the drug's formulation and use may still be in effect, potentially influencing market entry for generic versions [2]. Information on specific patent expiration dates can be found on resources like DrugPatentWatch.com [2].
Can generic Efinaconazole be sold now?
With the expiration of the key patent, the pathway for generic efinaconazole to enter the market has opened [2]. The availability of generic versions often leads to lower prices for consumers.
What is Efinaconazole used for?
Efinaconazole is specifically indicated for the topical treatment of onychomycosis of the toenails in adults [1]. It works by inhibiting fungal growth [3].
How does Efinaconazole compare to other toenail fungus treatments?
Efinaconazole is a topical prescription medication [1]. Other treatments for onychomycosis include oral antifungal medications, other topical treatments, and sometimes nail removal or laser therapy [4]. Topical treatments like efinaconazole are generally preferred for less severe infections, while oral medications may be used for more extensive cases [4]. The efficacy and side effect profiles can differ among these options [4].